title: Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
abstract: OBJECTIVE
  We evaluated the hypothesis that circulating tumor cells as determined using the CellSearch System would correlate with tumor volume, pathological stage and Gleason score in men with localized prostate cancer.
  
  
  METHODS
  Samples of blood (30 ml) were drawn from 97 men with localized prostate cancer before radical prostatectomy, on postoperative days 2 to 3 and at 6 weeks. A control group consisted of 25 men with an increased prostate specific antigen and no tumor detected on extended prostate biopsy. Samples were analyzed for circulating tumor cells using the CellSearch System.
  
  
  RESULTS
  Circulating tumor cells were detected in 21% of patients with cancer and 20% of controls (p = 0.946). At 6 weeks after prostatectomy circulating tumor cells were detected in 16% and 11% (p = 0.51) of the men positive and negative for circulating tumor cells at baseline, respectively. Of the 20 patients with cancer who had circulating tumor cells at baseline 18 showed no circulating tumor cells after surgery. Circulating tumor cell values did not correlate with tumor volume, pathological stage or Gleason score. Only 3.1% of the men with cancer and 8% of the control group had 3 or more circulating tumor cells per 22.5 ml blood at baseline.
  
  
  CONCLUSIONS
  In metastatic breast, prostate and other cancers more than 5 circulating tumor cells are often detected using the CellSearch System, and may correlate with prognosis. However, in the setting of localized prostate cancer the number of detectable circulating tumor cells was low, with findings comparable to those in men who were biopsy negative for cancer. We found no correlation between the number of circulating tumor cells and known prognostic factors in this population.
authors.affiliation: Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. JDHDavis@aol.com
authors.forename: John W
authors.initials: JW
authors.lastname: Davis
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Vikas S
authors.initials: VS
authors.lastname: Kumar
authors.forename: Viju A
authors.initials: VA
authors.lastname: Bhadkamkar
authors.forename: Robert
authors.initials: R
authors.lastname: McCormack
authors.forename: Herbert A
authors.initials: HA
authors.lastname: Fritsche
authors.forename: Beverly
authors.initials: B
authors.lastname: Handy
authors.forename: Terrie
authors.initials: T
authors.lastname: Gornet
authors.forename: R Joseph
authors.initials: RJ
authors.lastname: Babaian
mesh_terms: D000368:Aged; D003584:Cytological Techniques; D006801:Humans; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen